Ivermectin and Mebendazole for Brain Cancer: A Case Series of 123 Case Reports (April 2026 Update)
Abstract Glioblastoma and other high-grade brain tumors remain among the most lethal malignancies, characterized by aggressive growth, therapeutic resistance, and near-universal recurrence despite multimodal standard-of-care treatment. In recent years, drug repurposing has emerged as a promising strategy to accelerate the identification of novel anticancer therapies. Among these, the antiparasitic agents ivermectin and mebendazole have attracted increasing attention due to their demonstrated anticancer activity in preclinical models, including effects on cancer stem cells, tumor metabolism, microtubule dynamics, and signaling pathways relevant to glioma progression. This article presents a compilation of over 100 real-world case reports compiled between 2019 and 2026, involving patients with glioblastoma, astrocytoma, and other intracranial tumors who incorporated ivermectin and/or mebendazole into their treatment regimens. Reported outcomes include tumor stabilization, radiographic ...